Print

Purpose

The purpose of this study is to evaluate the efficacy and safety of expanded Xywav dosing regimens in adult participants with narcolepsy or idiopathic hypersomnia (IH).

Conditions

Eligibility

Eligible Ages
Between 18 Years and 75 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Has a primary diagnosis of IH or narcolepsy Type 1 or Type 2 (NT1 or NT2) 2. Participants with a primary diagnosis of NT1 must have a history of at least 14 cataplexy attacks in a typical 2-week period, based on participant history at the time of diagnosis and prior to initiating treatment. 3. Participants with a primary diagnosis of IH must have an average total nightly sleep time of at least 7 hours, based on participant history at the time of diagnosis and prior to initiating treatment. 4. If not currently treated with oxybate, has clinically significant symptoms of excessive daytime sleepiness (EDS) with an Epworth Sleepiness Scale (ESS) score > 11 at screening and baseline. 5. If currently treated with oxybate, must have documented improvement of EDS with oxybate treatment per the investigator's clinical judgement. 6. If currently treated with oxybate, has been taking the same stable dosing regimen at a total nightly dosage of 3 g to 9 g (inclusive) for at least 2 months at screening. 7. If previously treated with (and not currently taking) oxybate, must have been off oxybate treatment for at least 2 weeks prior to screening. Must not have previously discontinued oxybate due to reasons related to intolerability, safety, or lack of efficacy. 8. If currently treated with alerting agents, has been taking the same dosage for at least 1 month prior to screening and has no current plans to adjust the dosage during the study period. 9. If currently prescribed non-oxybate anticataplectic medications for cataplexy (NT1 only), must agree to taper off these medications (under the guidance and instruction of the investigator) during the OL-TOP and remain off these medications through the end of the DBRWP. 10. If currently treated with nicotine replacement therapy, has been taking the same dosage for at least 1 month prior to screening and has no current plans to adjust the dosage during the study period. 11. Adequate contraceptive precautions

Exclusion Criteria

  1. Shows evidence of a previous untreated or inadequately treated sleep disorder considered by the investigator to negatively impact the conduct of the study, including sleep-disordered breathing, parasomnias, circadian rhythm sleep disorders, or restless legs syndrome determined by a previous sleep-laboratory diagnosis or interview utilizing modules of the Diagnostic Interview for Sleep Patterns and Disorders. 2. Has succinic semi-aldehyde dehydrogenase deficiency by medical history. 3. Has uncontrolled hypothyroidism as determined by central clinical laboratory test results. 4. Has a current seizure disorder. 5. Has a history of head trauma associated with loss of consciousness in the past 5 years 6. Has a history or presence of bipolar disorder, bipolar-related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders 7. Has a history or presence of any unstable or clinically significant medical condition, behavioral or psychiatric disorder, or history or presence of another neurologic disorder or surgical history that might affect the participant's safety and/or interfere with the conduct of the study, in the opinion of the investigator. 8. Has any other significant disease or disorder that, in the opinion of the investigator, may either put the participant, other participants, or study staff at risk because of participation in the study, may influence the result of the study, or may affect the participant's safety or ability to take part in the study. 9. Any past or current medical conditions or experience that, in the investigator's clinical judgment, would preclude treatment with a once-nightly dose > 6 g up to 7.5 g dose or twice-nightly regimen with a total nightly dosage > 9 g up to 12 g (divided into 2 doses). 10. Has any severe drug allergy or a history of allergic or severe adverse reactions or intolerance to Xyrem, Xywav, Gamma-hydroxybutyrate (GHB), or any components of the dosage forms. 11. Has a history of substance abuse and/or a positive urine drug screen for drugs of abuse or alcohol 12. Has recently taken, is taking, or plans to take any of the following: 1. A substance or medication contraindicated with Xywav use 2. A medication with a known drug-drug interaction with Xywav 3. Medications known to have clinically significant CNS sedating effects 4. Other medications, natural health products, or substances from which the participant experiences clinically significant sedation 13. Has recently taken, is taking, or plans to take an Orexin 2 receptor (OX2R) agonist during the study. 14. Has tobacco-use disorder or uses vaping products that impact sleep 15. Has excessive caffeine consumption that may impact sleep 16. Has clinically significant abnormal laboratory values 17. Has an occupation that requires nighttime or variable shift work 18. Has plans for travel across more than 3 time zones during the study

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Narcolepsy Cohort once-nightly expanded Xywav dose group 		Participants with narcolepsy will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
Placebo Comparator
Narcolepsy Cohort once-nightly expanded Xywav followed by placebo group 		Participants with narcolepsy will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
  • Other: Placebo
    Placebo solution taken by mouth
Active Comparator
Narcolepsy Cohort twice-nightly expanded Xywav dose group 		Participants with narcolepsy will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
Placebo Comparator
Narcolepsy Cohort twice-nightly expanded Xywav followed by placebo group 		Participants with narcolepsy will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
  • Other: Placebo
    Placebo solution taken by mouth
Active Comparator
IH Cohort once-nightly expanded Xywav dose group 		Participants with IH will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
Placebo Comparator
IH Cohort once-nightly expanded Xywav followed by placebo group 		Participants with IH will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
  • Other: Placebo
    Placebo solution taken by mouth
Active Comparator
IH Cohort twice-nightly expanded Xywav dose group 		Participants with IH will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
Placebo Comparator
IH Cohort twice-nightly expanded Xywav followed by placebo group 		Participants with IH will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.
  • Drug: Xywav
    0.5 g/ml calcium, magnesium, potassium, and sodium oxybates solution taken by mouth
    Other names:
    • JZP258
  • Other: Placebo
    Placebo solution taken by mouth

Recruiting Locations

Santa Monica Clinical Trials
Los Angeles, California 90025

Intrepid Research
Cincinnati, Ohio 45245

Ohio Sleep Medicine and Neuroscience Institute
Dublin, Ohio 43017

More Details

Status
Recruiting
Sponsor
Jazz Pharmaceuticals

Study Contact

Clinical Trial Disclosure & Transparency
215-832-3750
ClinicalTrialDisclosure@JazzPharma.com

Detailed Description

The trial has 3 treatment periods: open label titration and optimization period (OL-TOP), stable dose period (SDP) and the double-blind randomized withdrawal period (DBRWP). Participants will be evaluated by their disease cohort (Narcolepsy and IH). Once eligibility to participate in the trial is confirmed, eligible participants will begin OL-TOP. Participants with narcolepsy and IH will be assigned to receive either a once-nightly expanded dosing of Xywav or a twice-nightly expanded dosing of Xywav. Assignment is dependent on participant's standard oxybate treatment and the treating investigator's decision. During OL-TOP, participants' Xywav dosing will be adjusted until they achieve a stable dose. This period can last up to 12 weeks. Once a stable dose is achieved, participants will begin the SDP. During the SDP, all participants will receive the stable Xywav dose for 2 additional weeks. Afterwards, the participants will begin the DBRWP. During this period, participants will be randomized to either continue on their stable dose of Xywav or receive placebo for 2 more weeks. In total, the participants will receive treatment in the trial for up to 16 weeks.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.